Iterum Therapeutics PLC
NASDAQ:ITRM

  • LAST PRICE
    1.8100
  • TODAY'S CHANGE (%)
    0.0400 (2.2599%)
  • Bid / Lots
    1.7600/ 15
  • Ask / Lots
    1.8100/ 20
  • Open / Previous Close
    1.8000 / 1.7700
  • Day Range
    1.6900
    1.8500
  • 52 Week Range
    0.8080
    2.5000
  • Volume
    827,144

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 21, 2024

  • Nov 14, 2024

      Show headlines and story abstract

    • 7:09AM ET on Thursday Nov 14, 2024 by MT Newswires
      Companies Mentioned: ITRM
      07:09 AM EST, 11/14/2024 (MT Newswires) -- ...

    • 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: ITRM

    • 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: ITRM

      This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding Iterum's plans, strategies and prospects for its business, including the development, therapeutic and market potential of ORLYNVAH(TM), the sufficiency of Iterum's cash resources to fund its operating expenses into 2025, the listing of patents for ORLYNVAH(TM) in the FDA's Orange Book and Iterum's strategic process to sell, license, or otherwise dispose of its rights to ORLYNVAH(TM). In some cases, forward-looking statements can be identified by words such as "may," "believes," "intends," "seeks," "anticipates," "plans," "estimates," "expects," "should," "assumes," "continues," "could," "would," "will," "future," "potential" or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum's control, including risks and uncertainties concerning the outcome, impact, effects and results of Iterum's evaluation of strategic alternatives, including the terms, timing, structure, value, benefits and costs of any strategic alternatives, Iterum's ability to complete a strategic alternative transaction, Iterum's ability to successfully prepare and implement commercialization plans for ORLYNVAH(TM) with a commercial partner or directly, including the Iterum's ability to build and maintain a sales force and prepare for commercial launch of ORLYNVAH(TM), if Iterum is unsuccessful at entering into or completing a strategic transaction, the ability of shareholders and other stakeholders to realize any value or recovery as part of a wind down process if Iterum is unsuccessful at entering into or completing a strategic transaction or preparing and implementing commercialization plans for ORLYNVAH(TM), the market opportunity for and the potential market acceptance of ORLYNVAH(TM) for uUTIs caused by certain designated microorganisms in adult women who have limited or no alternative oral antibacterial treatment options, uncertainties inherent in the conduct of clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, changes in public policy or legislation, commercialization plans and timelines, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of Iterum's expectations regarding how far into the future Iterum's cash on hand will fund Iterum's ongoing operations, Iterum's ability to maintain its listing on the Nasdaq Capital Market and other factors discussed under the caption "Risk Factors" in its Quarterly Report on Form 10-Q filed with the SEC on November 14, 2024, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum's beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Peers Headlines